BioXell is an Italian biopharmaceutical company developing innovative drug candidates for unmet medical needs in urology, inflammation and other selected areas. BioXell’s lead compound, Elocalcitol, is emerging as a potential new first-line monotherapy for lower urinary tract disorders, with a unique profile of action on the bladder and prostate and an outstanding safety record. BXL746, also derived from the Vitamin D3 class of compounds in which the Company has world-leading expertise, has generated highly positive preclinical data in the widespread and underserved indication post-surgical adhesions, and will be entering clinical trials in the second half of 2008.